dc.contributor | Departament de Salut |
dc.contributor.author | Programa d'Harmonització Farmacoterapèutica |
dc.date.accessioned | 2021-03-03T11:09:46Z |
dc.date.available | 2021-03-03T11:09:46Z |
dc.date.issued | 2020-07-07 |
dc.identifier.citation | Programa d'Harmonització Farmacoterapèutica. Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics. Barcelona: Servei Català de la Salut; 2020. |
dc.identifier.uri | https://hdl.handle.net/11351/5674 |
dc.description | Luteci oxodotreotida; Radiopharmaceutical; Gastroenteropancreatic neuroendocrine tumors |
dc.description.abstract | Neuroendocrine tumors (TNEs) are defined as those neoplasms with a predominantly neuroendocrine cell differentiation, which can arise in most organs, although most are of gastrointestinal or pancreatic origin (≈65%). The Spanish Group of Neuroendocrine and Endocrine Tumors (GETNE) groups tumors of the digestive tract and pancreas with the term gastroenteropancreatic neuroendocrine tumors (TNE-GEP). In general, they are tumors with a low incidence, between 1-7 new cases approximately per 100,000 inhabitants annually. The incidence, depending on the location of the primary tumor, is approximately 3.6 cases / 100,000 for TNE-GEPs, 1.5 cases / 100,000 for those of pulmonary origin and 0.8 cases / 100,000 for tumors of unknown origin. The incidence is slightly higher for men than for women, with an age at diagnosis around 50. |
dc.language.iso | cat |
dc.publisher | Servei Català de la Salut |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Tumors neuroendocrins - Tractament |
dc.subject | Radiofàrmacs |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Lutetium |
dc.subject.mesh | Neuroendocrine Tumors |
dc.subject.mesh | Drug Evaluation |
dc.subject.mesh | /drug therapy |
dc.title | Luteci (177Lu) oxodotreotida per al tractament de tumors neuroendocrins gastroenteropancreàtics positius al receptor de somatostatina, ben diferenciats, progressius i irresecables o metastàtics |
dc.type | info:eu-repo/semantics/report |
dc.subject.decs | lutecio |
dc.subject.decs | tumores neuroendocrinos |
dc.subject.decs | evaluación de medicamentos |
dc.subject.decs | /farmacoterapia |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |